Search results
Results From The WOW.Com Content Network
Erectile dysfunction (ED), also referred to as impotence, is a form of sexual dysfunction in males characterized by the persistent or recurring inability to achieve or maintain a penile erection with sufficient rigidity and duration for satisfactory sexual activity.
Venous leak, also called venogenic erectile dysfunction and penile venous insufficiency, is one category of vascular-induced (vasculogenic) impotence – a cause of erectile dysfunction in males. [2] It affects all ages, being particularly awkward in young men. [ 3 ]
A common cause of anorgasmia, in both women and men, is the use of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs). Though reporting of anorgasmia as a side effect of SSRIs is not precise, studies have found that 17–41% of users of such medications are affected by some form of sexual dysfunction.
Erectile dysfunction (ED), or impotence, is a sexual dysfunction characterized by the inability to develop or maintain an erection of the penis. There are various underlying causes of ED, including damage to anatomical structures, psychological causes, medical disease, and drug use.
The ICD-11 replaces these with two main categories: Hypoactive sexual desire dysfunction and Sexual arousal dysfunction . The latter has two subcategories: Female sexual arousal dysfunction and Male erectile dysfunction . The difference between Hypoactive sexual desire dysfunction and Sexual arousal dysfunction is that in the former, there is a ...
In January 2020, Ro partnered with Pfizer for the sourcing of Sildenafil. [16] In July 2020, Ro raised $200 million in a series C funding round. [ 17 ] In March 2021, Ro raised $500 million in a series D funding round led by General Catalyst, FirstMark Capital, and TQ Ventures, giving the company a $5 billion valuation. [ 18 ]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Marked as VyleesiTM, it was primarily designed for both men and women in the form of an intranasal formulation, particularly for treating male erectile dysfunction. [23] However, the research was discontinued and focused on targeting female HSDD [23] in a subcutaneous injection to increase bioavailability. [3]